Gustave Roussy

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.

THERYQ and Gustave Roussy have been selected as part of the "i-Démo" France 2030 call for projects, operated on behalf of the French government by Bpifrance, for the "FLASHDEEP" project, for an amount of 38 million euros

Retrieved on: 
Friday, February 2, 2024

FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).

Key Points: 
  • FLASHDEEP will be the world's first FLASH radiotherapy device using very high-energy electrons (VHEE; > 100 MeV).
  • The particle acceleration technology developed by THERYQ stems from research initiated by the European Organization for Nuclear Research (CERN) and the University Hospital of Lausanne (CHUV).
  • The first clinical FLASHDEEP device will be installed in France, at Gustave Roussy, late 2026, to conduct clinical trials with eligible patients.
  • Ultimately, it will lead to the revival of a French radiotherapy industrial sector, a field that has been neglected since the late 1980s.

Sofinnova Partners and Gustave Roussy forge strategic alliance to boost oncology startup acceleration in France

Retrieved on: 
Wednesday, December 13, 2023

Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “Gustave Roussy is a European oncology powerhouse, which aligns seamlessly with Sofinnova Biovelocita, our newly launched biotech acceleration strategy.

Key Points: 
  • Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “Gustave Roussy is a European oncology powerhouse, which aligns seamlessly with Sofinnova Biovelocita, our newly launched biotech acceleration strategy.
  • This alliance reaffirms our commitment to fostering a thriving French biotech ecosystem.”
    Prof. Fabrice Barlesi, General Director of Gustave Roussy and CEO from Gustave Roussy Transfert, said: "Gustave Roussy and Sofinnova will work together to invest in projects focused on the discovery and development of new molecules and innovative technologies led or initiated by Gustave Roussy.
  • Gustave Roussy Transfert aims to create and support one or two new oncology startups per year over the next five years within Biovelocita.
  • A first project sourced by Gustave Roussy Transfert and presented to Sofinnova Biovelocita should soon pass through the investment committee, with a first company inception planned for early 2024.

RenovoRx Expands Scientific Advisory Board with Appointment of Michel Ducreux, M.D., Ph.D.

Retrieved on: 
Thursday, November 16, 2023

(“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB).

Key Points: 
  • (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a clinical-stage biopharmaceutical company developing targeted combination therapies, today announced the appointment of Michel Ducreux, M.D., Ph.D. to the Company’s Scientific Advisory Board (SAB).
  • Dr. Ducreux was trained in medicine, gastroenterology, and gastrointestinal tract oncology at the University of Paris Sud.
  • Dr. Ducreux earned his master’s degree in biological sciences and PhD in health sciences.
  • “I am excited to be working with my distinguished colleagues on RenovoRx’s Scientific Advisory Board,” stated Dr. Ducreux.

Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress

Retrieved on: 
Monday, October 16, 2023

PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 , to take place on October 20-23, 2023 in Madrid, Spain.

Key Points: 
  • PARIS, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that updated data from its Phase 1/2 SPENCER study on EO2401, in combination with nivolumab in patients with adrenal tumors, will be presented in an oral session at the European Society for Medical Oncology (ESMO) Congress 2023 , to take place on October 20-23, 2023 in Madrid, Spain.
  • Dr. Eric Baudin, Associate Professor and Head of the Endocrine Oncology Unit at Gustave Roussy (Villejuif, France)

Orakl Oncology raises €3 million to develop its techbio platform for precision oncology

Retrieved on: 
Wednesday, October 4, 2023

Orakl Oncology , a precision oncology start-up, today announces that it has raised €3 million to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate oncology drug development.

Key Points: 
  • Orakl Oncology , a precision oncology start-up, today announces that it has raised €3 million to develop its techbio platform that integrates best-in-class biology with real-world patient data at scale to accurately model tumors and accelerate oncology drug development.
  • A major challenge in oncology is that drug candidates meet patients too late in the development process.
  • Dr. Fanny Jaulin, Orakl Oncology CEO & Co-Founder, commented, “Our ambition is to become a world-leading techbio platform leveraging the smartest collection of tumor avatars to transform oncology drug development and bring faster, smarter and more cost-effective treatments to patients.
  • They aim to disrupt precision oncology by leveraging major academic and pharma partnerships to accelerate drug development, ultimately leading to better patient outcomes."

LinKinVax and Gustave Roussy Announced First Patient Dosed in Phase I/IIa Clinical Study on HPV.DCVax in HPV-positive Oropharyngeal Cancer

Retrieved on: 
Monday, September 18, 2023

LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.

Key Points: 
  • LinKinVax, a clinical-stage biotechnology company focusing on innovative protein-based vaccines, and Gustave Roussy, the leading cancer centre in Europe ranked third Best Cancer Hospital in the world, announced the treatment at Gustave Roussy of the first patient in a Phase I/IIa clinical study with CD40HVac, a new therapeutic vaccine candidate for HPV-positive oropharyngeal cancer.
  • This multicentre study will test 2 doses of CD40HVac using a dose escalation regimen.
  • Up to 24 patients will be recruited in this double-blind, randomised and placebo-controlled study.
  • Valérie Bouchara, Head of Clinical Operations at LinKinVax, commented: "This first administration is a major milestone in the development of our therapeutic cancer vaccine CD40HVac.

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

Retrieved on: 
Wednesday, September 6, 2023

Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies.

Key Points: 
  • Veracyte, Inc. (Nasdaq: VCYT), a global diagnostics company, and Gustave Roussy, a leading cancer center worldwide, announced today that they have entered into a collaboration to bring together their respective capabilities to provide novel insights into the underlying biology of metastatic tumors, which may help biopharmaceutical companies accelerate development of new cancer therapies.
  • Veracyte will combine these assets with its multi-omics testing and machine learning capabilities to create a Veracyte Biopharma Atlas reference database of genomic and immunomic biomarkers.
  • “This partnership will enable us to augment our Veracyte Biopharma Atlas reference database with a large number of patients tumor samples and data from innovative cancer therapies.
  • Ultimately, we believe this tool may help our biopharmaceutical partners accelerate development of new, precision-medicine therapies that improve outcomes for patients with cancer.”

SOPHiA GENETICS Expands Relationship with Gustave Roussy

Retrieved on: 
Tuesday, August 22, 2023

BOSTON and ROLLE, Switzerland, Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe. With the expanded relationship SOPHiA GENETICS will now further support Gustave Roussy via the SOPHiA DDM™ Platform, which will provide expedited analysis and insights of genomic profiles.

Key Points: 
  • Gustave Roussy uses SOPHiA DDM™ Platform to empower confident, data-driven medicine in the fight against cancer
    BOSTON and ROLLE, Switzerland, Aug. 22, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe.
  • With the expanded relationship SOPHiA GENETICS will now further support Gustave Roussy via the SOPHiA DDM™ Platform, which will provide expedited analysis and insights of genomic profiles.
  • The SOPHiA DDM™ Platform, a recognized solution in terms of quality – ISO13485 and ISO27001 - and performance, was the optimal solution for Gustave Roussy," said Etienne Rouleau, Head of Genetics Unit at Gustave Roussy.
  • Gustave Roussy has updated its Laboratory Information Management System (LIMS) to create bi-directional communication between the existing Gustave Roussy database and the SOPHiA DDM™ Platform.